Investment activity Gilgamesh Pharma secured a $60 million Series A financing in March 2026, signaling strong investor confidence and potential readiness for partnering on late-stage development, manufacturing partnerships, or co-development agreements to accelerate therapeutic programs.

Therapeutic focus The company is pursuing rapid-acting, durable therapies targeting core drivers of psychiatric and neurological diseases, including derivative ibogaine options for PTSD and substance use disorders, suggesting opportunities for collaborations in CNS drug development, safety profiling, or companion diagnostic strategies.

Regulatory leadership Appointment of a VP Regulatory Affairs and a track record of navigating complex clinical programs indicate readiness for regulatory strategy outsourcing, submissions support, and global regulatory alignment services to accelerate INDs/clinical trial approvals.

Strategic interest from acquirers Industry chatter and press coverage around AbbVie potentially acquiring Gilgamesh imply heightened drama for business development outreach; target conversations around licensing, acquisition readiness, or strategic partnerships to monetize late-stage assets.

Clinical-stage growth With a clinical-stage profile, ongoing trials for PTSD and major depressive disorder plus a cardiac-safety IBogaine derivative, there are opportunities to engage on CRO/CMO partnerships, specialized toxicology services, and early-phase trial execution support to advance development timelines.